Research and Development

Rail Vision Subsidiary Achieves Quantum Error Correction Milestone Using Google Quantum AI Dataset

Rail Vision Subsidiary Achieves Quantum Error Correction Milestone Using Google Quantum AI Dataset

Rail Vision Ltd.'s majority-owned subsidiary, Quantum Transportation Ltd., has successfully integrated Google Quantum AI's experimental surface-code dataset into its quantum error correction pipeline, advancing quantum decoding technology and reducing technical risk.

May 20, 2026
Delta Gold Technologies Featured in Debut Episode of The Innovation Report Series on Quantum Technologies

Delta Gold Technologies Featured in Debut Episode of The Innovation Report Series on Quantum Technologies

Delta Gold Technologies PLC is featured in the first episode of The Innovation Report Series, highlighting the commercial potential of quantum technologies and their impact across industries.

May 11, 2026
Creative Biogene Expands Antibody Purification Platform to Support Biotechnology Innovation

Creative Biogene Expands Antibody Purification Platform to Support Biotechnology Innovation

Creative Biogene's enhanced antibody purification platform offers scalable, high-yield purification solutions critical for advancing biotech research and development.

August 21, 2025
BIO 2025 Trend Report Highlights Biotech's Shift Towards Scalability and Human-Centric Innovation

BIO 2025 Trend Report Highlights Biotech's Shift Towards Scalability and Human-Centric Innovation

The BIO 2025 Pulse of the Industry Report by Norvell Jefferson underscores the biotech sector's evolution towards scalable, meaningful innovations that prioritize human-centric approaches and strategic branding.

July 31, 2025
Fifty 1 Labs to Host Virtual Shareholder Teleconference Featuring Nobel Laureate Dr. James Orbinski

Fifty 1 Labs to Host Virtual Shareholder Teleconference Featuring Nobel Laureate Dr. James Orbinski

Fifty 1 Labs announces a virtual shareholder teleconference to discuss its strategic roadmap, including AI-driven drug repurposing and significant R&D investments, highlighting its commitment to innovation in health and wellness.

July 28, 2025
Oragenics Inc. Announces $20 Million Preferred Stock and Warrant Offering to Fund Concussion Trials and R&D

Oragenics Inc. Announces $20 Million Preferred Stock and Warrant Offering to Fund Concussion Trials and R&D

Oragenics Inc. secures up to $20 million through a preferred stock and warrant offering to advance its ONP-2 concussion trials and support R&D efforts.

July 1, 2025
Glidelogic's AI Research Platform Approaches Top Industry Benchmarks

Glidelogic's AI Research Platform Approaches Top Industry Benchmarks

Glidelogic's ResearchMind AI platform achieves near-top scores in independent testing, demonstrating significant advancements in AI research technology that could dramatically reduce research proposal development time.

April 22, 2025